An FDA advisory panel votes against recommending a new diabetes drug being developed by AstraZeneca (AZN) and Bristol-Myers (BMY), questioning whether there's sufficient efficacy and safety data to support the drug's approval. AstraZeneca -0.7% in London.
An FDA advisory panel votes against recommending a new diabetes drug being developed by...
From other sites
Video at CNBC.com (Jun 6, 2016)
Video at CNBC.com (Jun 3, 2016)
Video at CNBC.com (Apr 7, 2016)
at CNBC.com (Jun 1, 2015)
Video at CNBC.com (Feb 11, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs